Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PARP”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT06380660
What this trial is testing

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumor, AdultBRCA1 MutationBRCA2 Mutation+3 more
Acerand Therapeutics (Shanghai) Limited 298
Early research (Phase 1)Looking for participantsNCT06856499
What this trial is testing

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

Who this might be right for
Endometrioid Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
University of Colorado, Denver 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT04039230
What this trial is testing

Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.

Who this might be right for
Breast Cancer
Massachusetts General Hospital 75
Not applicableLooking for participantsNCT06197581
What this trial is testing

Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer

Who this might be right for
Breast Cancer, Familial MaleRadiotherapy; ComplicationsChemotherapeutic Toxicity+5 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 148
Post-approval studies (Phase 4)UnknownNCT05187208
What this trial is testing

PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer

Who this might be right for
Epithelial Ovarian CancerOvarian CancerOvarian Cancer Stage III+1 more
Seoul National University Hospital 102
Testing effectiveness (Phase 2)UnknownNCT05489926
What this trial is testing

Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure

Who this might be right for
Epithelial Ovarian Cancer
Zhejiang Cancer Hospital 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT04550494
What this trial is testing

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Castration-Resistant Prostate Carcinoma+28 more
National Cancer Institute (NCI) 29
Testing effectiveness (Phase 2)Study completedNCT01306032
What this trial is testing

Phase II ABT-888 With Cyclophosphamide

Who this might be right for
Ovarian CancerPrimary Peritoneal CancerSerous Carcinoma Cancer+2 more
National Cancer Institute (NCI) 124
Testing effectiveness (Phase 2)Study completedNCT02305758
What this trial is testing

Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer

Who this might be right for
Untreated Metastatic Colorectal Cancer
AbbVie 130
Not applicableNot Yet RecruitingNCT06139783
What this trial is testing

Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors

Who this might be right for
Ovarian Cancer
Oncare Madrid 32
Very early researchStudy completedNCT04041128
What this trial is testing

PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer

Who this might be right for
Ovarian CancerBreast Cancer
University of Texas Southwestern Medical Center 14
Early research (Phase 1)Study completedNCT00710268
What this trial is testing

Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours

Who this might be right for
Neoplasm Metastasis
AstraZeneca 18
Testing effectiveness (Phase 2)UnknownNCT03925350
What this trial is testing

Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation

Who this might be right for
Metastatic Melanoma
California Pacific Medical Center Research Institute 41
Not applicableLooking for participantsNCT06200558
What this trial is testing

ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa

Who this might be right for
Prostate Cancer
Hospital of Macerata 534
Not applicableUnknownNCT05044091
What this trial is testing

Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients

Who this might be right for
Ovarian CancerHRDPARP Inhibitor
Xiaoxiang Chen 100
Early research (Phase 1)Looking for participantsNCT05942300
What this trial is testing

CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Who this might be right for
Recurrent Ovarian Cancer
Lan Coffman 30
Early research (Phase 1)Looking for participantsNCT06930755
What this trial is testing

Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

Who this might be right for
Ovarian Cancer
Nerviano Medical Sciences 24
Early research (Phase 1)Study completedNCT00516724
What this trial is testing

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

Who this might be right for
Triple Negative Metastatic Breast CancerAdvanced Ovarian CancerCarboplatin+1 more
AstraZeneca 189
Testing effectiveness (Phase 2)Study completedNCT01033123
What this trial is testing

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
Sanofi 41
Early research (Phase 1)Study completedNCT01247168
What this trial is testing

An Open-Label, Dose-Escalation Study of AZD2461

Who this might be right for
Refractory Solid TumorsCancer Tumor
AstraZeneca 75
Next Page